Tocainide-Associated Interstitial Pneumonitis
Authors: GERALD M. PERLOW
Journal: Annals of Internal Medicine (1981)

Brief Reports1 April 1981Tocainide-Associated Interstitial PneumonitisGERALD M. PERLOW, M.D., BIMAL P. JAIN, M.D., STEPHEN G. PAUKER, M.D., HARVEY S. ZARREN, M.D., DANIEL C. WISTRAN, M.D., RALPH L. EPSTEIN, M.D.GERALD M. PERLOW, M.D.Search for more papers by this author, BIMAL P. JAIN, M.D.Search for more papers by this author, STEPHEN G. PAUKER, M.D.Search for more papers by this author, HARVEY S. ZARREN, M.D.Search for more papers by this author, DANIEL C. WISTRAN, M.D.Search for more papers by this author, RALPH L. EPSTEIN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-94-4-489 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTocainide, an investigational antiarrhythmic drug with chemical and pharmacologic properties similar to those of lidocaine, is effective when administered orally in treating ventricular arrhythmias (1-4). At present tocainide is not in clinical use in the United States or Europe, but its efficacy strongly suggests that it will soon be introduced for clinical use. Typical doses are between 400 and 800 mg every 8 hours. The commonest side effects have been anorexia, nausea, lightheadedness, tremors, sweating, hot flashes, anxiety, paresthesia, vomiting, abdominal pain, and altered vision and hearing. No pulmonary complications appear to have been reported. A single reported incident of...References1. Investigators Brochure for Tocaine HC1. Framingham, Massachusetts: Astra Pharmaceutical Products; 1977. Google Scholar2. WINKLE R, MEFFIN P, and HARRISON D. Long-term tocainide therapy for ventricular arrhythmias. Circulation. 1978;57:1008-16. CrossrefMedlineGoogle Scholar3. ANDERSON J, MASON J, and WINKLE R. Clinical electrophysiological effects of tocainide. Circulation. 1978;57:685-91. CrossrefMedlineGoogle Scholar4. WOOSLEY R, MCDEVITT D, NIES A, SMITH R, WILKINSON G, and OATES J. Suppression of ventricular ectopic depolarizations by tocainide. Circulation. 1977;56:980-4. CrossrefMedlineGoogle Scholar5. ROSENOW E, DEREMEE R, and DINES D. Chronic nitrofurantoin pulmonary reaction: report of five cases. N Engl J Med. 1968;279:1258-62. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: GERALD M. PERLOW, M.D.; BIMAL P. JAIN, M.D.; STEPHEN G. PAUKER, M.D.; HARVEY S. ZARREN, M.D.; DANIEL C. WISTRAN, M.D.; RALPH L. EPSTEIN, M.D.Affiliations: Lynn Hospital Lynn, Massachusetts Tufts-New England Medical Center Boston, Massachusetts PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byTocainideANTIDYSRHYTHMIC DRUGSADVERSE CARDIOVASCULAR EFFECTS OF NON-CARDIOVASCULAR DRUGSTocainideDrug-induced Pulmonary DisordersSystemic local-anaesthetic-type drugs in chronic pain: A systematic reviewPossible Association of Pulmonary Fibrosis with MexiletineAntiarrhytmic: AgentsCLASS IA AND CLASS IB ANTIARRHYTHMIC DRUGS - A Review of Their Pharmacokinetics, Electrophysiology, Efficacy, and ToxicityTocainide: Interstitial pneumonitisDrug-Induced Pulmonary ReactionsPulmonary and Pleural Complications of Cardiac DiseaseVentricular arrhythmiasClinical Use of Class Ib Antiarrhythmic DrugsTocainide: A Severe Adverse ReactionCLASS IA AND CLASS IB ANTIARRHYTHMIC DRUGS ? A Review of Their Pharmacokinetics, Electrophysiology, Efficacy, and ToxicityPharmacokinetics and pharmacodynamics of antiarrhythmic agents in patients with congestive heart failureEfficacy and tolerance of tocainide during long-term treatment of malignant ventricular arrhythmiasTreatment of Paramyotonia Congenita with AcetazolamideDrug-induced pulmonary diseaseTocainideEfficacy and Safety of Oral Tocainide in Refractory Ventricular Arrhythmia: A Preliminary Report on an Open Label StudyBronchial inflammatory reactionsTocainide: A New Oral Antiarrhythmic AgentSTEVEN P. KUTALEK, M.D., JOEL MORGANROTH, M.D., LEONARD N. HOROWITZ, M.D.Tocainide: A New Oral AntiarrhythmicTherapy with Conventional Antiarrhythmic Drugs for Ventricular ArrhythmiasTherapy with Investigational Antiarrhythmic DrugsChemistry, Pharmacology, Antiarrhythmic Efficacy and Adverse Effects of Tocainide Hydrochloride, An Orally Active Structural Analog of LidocaineCommentary 1Clinical profiles of newer class I antiarrhythmic agents—Tocainide, mexiletine, encainide, flecainide and lorcainideCardiac glycosides and drugs used in dysrhythmiasTocainide-associated interstitial pneumonitis.Cardiac glycosides and drugs used in dysrhythmias 1 April 1981Volume 94, Issue 4_Part_1Page: 489-490KeywordsAnxietyArrhythmiaCareers in researchDrugsHearingInterstitial lung diseasesNauseaRisk managementVisionVomiting ePublished: 1 December 2008 Issue Published: 1 April 1981 PDF downloadLoading ...